… -cell carcinoma (SCC) of … erlotinib and afatinib in SCC of the lung. The authors explore the
rationale of targeting EGFR in SCC and the pharmacological properties of erlotinib and afatinib…

… (afatinib, gefitinib, and erlotinib). We found that gefitinib was more commonly used than
erlotinib or afatinib … Afatinib was more commonly used for patients with tumors harboring Del19. …

… This study shows that afatinib has clinical efficacy as second-line treatment for patients with
… cell carcinoma of the lung. Afatinib reduced the risk of death compared with erlotinib and …

… However, afatinib was more effective than erlotinib as second-line treatment of patients …
cell carcinoma. The grade 3/4 adverse events rate of afatinib was comparable to that of erlotinib …

8002 Background: Treatment options for pts with advanced SCC of the lung progressing after
platinum-based chemotherapy are limited. Overexpression of EGFR, ErbB receptors and …

… LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib
as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the …

… Afatinib is a cost-effective treatment option compared with erlotinib in patients with squamous
cell carcinoma… Here, we compared the cost–effectiveness of afatinib to that of erlotinib for …

… tumors with at least 1 ERBB mutation. Although progression-free survival and overall survival
… improved with afatinib vs erlotinib treatment among patients with ERBB wild-type tumors, …

Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …

… 19-deleted tumors appeared to have a greater benefit from afatinib (HR 0.28, … afatinib (BIBW
2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib…